Related Experiment Videos

Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome

Patricia Woo1

  • 1Paediatric Rheumatology, Institute of Child Health and the Royal Free and University College Medical School, London, UK. patricia.woo@ucl.ac.uk

Nature Clinical Practice. Rheumatology
|August 26, 2006
PubMed

Insights

Systemic juvenile idiopathic arthritis (SJIA) is a severe childhood arthritis with high morbidity and poor treatment outcomes. New therapies like stem-cell transplantation and IL-6 blockade show promise for improving patient prognosis.

Area of Science:

  • Pediatrics
  • Rheumatology
  • Immunology

Background:

  • Systemic juvenile idiopathic arthritis (SJIA) is a significant childhood rheumatic disease, affecting 10-20% of pediatric arthritis cases in Caucasian populations.
  • A substantial proportion of SJIA patients (up to 30%) experience persistent active disease for over a decade, leading to high morbidity.
  • Medical sequelae include growth failure, osteoporosis, deformities, and functional loss, alongside significant developmental and social challenges.

Purpose of the Study:

  • To review the current understanding of systemic juvenile idiopathic arthritis (SJIA).
  • To highlight the unmet medical needs in treating severe SJIA.
  • To discuss emerging therapeutic strategies under investigation.

Main Methods:

  • Literature review of systemic juvenile idiopathic arthritis (SJIA).
  • Analysis of disease characteristics, complications, and treatment outcomes.
  • Overview of ongoing clinical trials for novel SJIA therapies.

Main Results:

  • SJIA is a heterogeneous condition with severe long-term consequences.
  • Current treatments for severe SJIA are often unsatisfactory.
  • High morbidity and significant secondary complications are observed in a large subset of patients.

Conclusions:

  • SJIA poses a considerable burden on affected children, impacting physical, developmental, and social well-being.
  • There is a critical need for more effective treatments for severe SJIA.
  • Emerging therapies, including autologous stem-cell transplantation and IL-6 pathway inhibition, offer potential for improved outcomes in SJIA management.

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...